

1F-660-T100

## Monoclonal Antibody to CD150 Fluorescein (FITC) conjugated (100 tests)

Clone: SLAM.4

**Isotype:** Mouse IgG1

Specificity: The mouse monoclonal antibody SLAM.4 recognizes CD150, a cell surface

molecule expressed on lymphocytes and involved in their activation.

Regulatory Status: RUO

Immunogen: Human CD150-transfected 300.19 cells

Species Reactivity: Human

Preparation: The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under

optimum conditions. The reagent is free of unconjugated FITC and adjusted for

direct use. No reconstitution is necessary.

Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution

containing 15mM sodium azide.

Storage / Stability: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not

use after expiration date stamped on vial label.

**Usage:** The reagent is designed for Flow Cytometry analysis of human blood cells using 4

μl reagent / 100 μl of whole blood or 10<sup>6</sup> cells in a suspension.

The content of a vial (0.4 ml) is sufficient for 100 tests.

**Expiration:** See vial label

**Lot Number:** See vial label

**Background:** CD150, also known as SLAM (signaling lymphocyte activation molecule) is a 70-95

kDa single chain transmembrane phosphoglycoprotein of the CD2 family. Its extracellular part contains eight potential N-glycosylation sites, and the intracellular tail contains three unique tyrosine-based motifs. These binding sites can be recognized by SH2-binding phosphatases and the adaptor proteins, such as SAP/SH2D1A or EAT-2. The SLAM family receptors are involved in leucocyte activation and contribute to the effective germinal center formation, generation of high-affinity antibody-secreting plasma cells, and memory T and B cells, thereby facilitating long-term immune response. CD150 expression is upregulated after cell

activation.



## PRODUCT DATA SHEET

## References:

\*García VE, Quiroga MF, Ochoa MT, Ochoa L, Pasquinelli V, Fainboim L, Olivares LM, Valdez R, Sordelli DO, Aversa G, Modlin RL, Sieling PA: Signaling lymphocytic activation molecule expression and regulation in human intracellular infection correlate with Th1 cytokine patterns. J Immunol. 2001 Nov 15;167(10):5719-24.

\*Romero X, Martin M, Zapater N, Tovar V, Pizcueta P, Engel P: Expression of CD150 on human leukocytes. Production and characterisation of a new CD150 monoclonal antibody

De Salort J, Sintes J, Llinàs L, Matesanz-Isabel J, Engel P: Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: from pro-B to plasma cells. Immunol Lett. 2011 Jan 30;134(2):129-36.

\*Romero X, Benítez D, March S, Vilella R, Miralpeix M, Engel P: Differential expression of SAP and EAT-2-binding leukocyte cell-surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4). Tissue Antigens. 2004 Aug;64(2):132-44.

\*Romero X, Zapater N, Calvo M, Kalko SG, de la Fuente MA, Tovar V, Ockeloen C, Pizcueta P, Engel P: CD229 (Ly9) lymphocyte cell surface receptor interacts homophilically through its N-terminal domain and relocalizes to the immunological synapse. J Immunol. 2005 Jun 1;174(11):7033-42.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.